Welcome to our dedicated page for Waters SEC filings (Ticker: WAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Waters Corporation (NYSE: WAT) filings with the U.S. Securities and Exchange Commission (SEC), along with AI-generated summaries to help interpret key disclosures. Waters files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that cover its operations in analytical instruments, separations technologies, and software serving the life, materials, food, and environmental sciences.
For Waters, 10-K and 10-Q filings are central resources for understanding its business segments, end markets, and risk factors. These documents discuss topics such as the company’s role in pharmaceutical, industrial, and academic/government applications, as well as its global footprint in over 100 countries. AI summaries can highlight sections related to recurring revenue, instrument trends, and investments in areas like bioanalytical characterization and bioseparations.
Form 8-K filings are particularly important for tracking material events. Recent 8-Ks describe quarterly financial results, provide press releases as exhibits, and outline the definitive agreements for a Reverse Morris Trust transaction that will combine BD’s Biosciences and Diagnostic Solutions business with Waters. Other 8-Ks discuss the effectiveness of registration statements on Form S-4 and Form 10 related to that transaction and the mailing of a proxy statement/prospectus to Waters shareholders.
Investors can also use this page to locate information on governance matters and potential insider activity through ownership reports referenced in Waters’ filings. Real-time updates from EDGAR, combined with AI-powered explanations, are intended to make complex regulatory documents more accessible by summarizing key terms, conditions, and implications for WAT shareholders and stakeholders following Waters’ evolution in life science and diagnostics markets.
Waters Corporation is offering $3,500,000,000 of senior notes through its subsidiary Augusta SpinCo Corporation. The offering comprises five series of senior unsecured notes: $650,000,000 4.321% due September 23, 2027, $600,000,000 4.398% due March 23, 2029, $750,000,000 4.656% due March 23, 2031, $750,000,000 4.945% due March 23, 2033, and $750,000,000 5.245% due March 23, 2036.
The Notes will be senior unsecured obligations of Augusta and will be fully and unconditionally guaranteed on a senior unsecured basis by Waters Corporation and specified subsidiaries. The Issuer intends to use the net proceeds, together with cash on hand, to repay borrowings under the Augusta Delayed Draw Term Loan Facility.
Waters Corp director Wei Jiang bought 500 shares of common stock in an open-market transaction at $289.46 per share. After this purchase, Jiang directly owns 3,441.27 Waters shares, increasing their personal stake in the company.
Waters Corporation filed an automatic shelf registration to offer an indeterminate amount of common stock, preferred stock, debt securities, guarantees, warrants and other instruments from time to time after this Registration Statement becomes effective. The prospectus permits offerings by Waters and by affiliated issuers Augusta SpinCo Corporation and Waters Technologies Corporation, with certain debt of Augusta and WTC to be guaranteed by Waters.
The shelf incorporates summarized financials for the consolidated Waters group and for the acquired BDS Business; Waters completed the business combination with the BDS Business on February 9, 2026. As of February 19, 2026, Waters reports 98,101,871 shares of common stock issued and outstanding. Offering terms, proceeds treatment and specific guarantors will be stated in any prospectus supplement.
Waters Corporation filed a Form 8-K to provide detailed historical and pro forma financial information for Becton, Dickinson’s former Biosciences and Diagnostic Solutions business acquired on February 9, 2026. The filing includes unaudited condensed combined financial statements, multi-year MD&A, and pro forma combined results for Waters and the acquired business.
For the three months ended December 31, 2025, the BDS Business generated revenues of $766 million, down from $834 million a year earlier, with net income of $49 million versus $78 million. Operating income fell to $35 million from $94 million, and gross margin declined as higher tariffs and labor costs more than offset productivity gains.
Segment data show Biosciences quarterly revenue of $327 million and Diagnostic Solutions revenue of $439 million, both lower than the prior year. For BD’s fiscal year 2025, the BDS Business reported worldwide revenues of $3,296 million, slightly below 2024, but maintained solid profitability with segment operating margins in the mid-teens to mid-30% range.
Waters Corporation director Richard H. Fearon bought 1,000 shares of common stock in an open-market transaction on March 6, 2026. The shares were purchased at a weighted average price of $306.34 per share, with individual trade prices ranging from $305.84 to $306.49. Following this purchase, he directly holds 3,302 Waters shares.
Waters Corporation President and CEO Udit Batra reported an automatic share disposition related to tax withholding. On this Form 4, 3,417 shares of common stock were withheld by the company at a price of $307.23 per share to cover tax obligations tied to vesting performance stock units.
These shares were not sold in an open-market transaction but were retained by the issuer to satisfy withholding requirements. After this tax-withholding disposition, Batra directly owned 33,140 shares of Waters common stock.
Waters Corp senior vice president and chief financial officer Amol Chaubal reported an insider transaction related to equity compensation. On this Form 4, 709 shares of common stock were withheld by the company on March 2, 2026 to satisfy tax obligations tied to the vesting of previously reported performance stock units, at a price of $307.23 per share. This was a tax-withholding disposition rather than an open-market sale. After this withholding, Chaubal directly holds 7,796.393 shares of Waters common stock.
Waters Corporation senior vice president Jianqing Bennett reported a tax-related share disposition. On this Form 4, 410 shares of common stock were withheld by the company at a price of $307.23 per share to satisfy tax withholding obligations tied to vesting of previously reported performance stock units. After this withholding, Bennett directly owns 6,834 shares of Waters common stock.
Carpio Robert L III reported acquisition or exercise transactions in this Form 4 filing.
Waters Corp senior vice president Robert L. Carpio III received new equity awards, not open-market purchases or sales. He was granted 4,884 stock options and 997 restricted stock units as of February 25, 2026. The options and RSUs both vest in four equal annual installments starting on February 25, 2027, contingent on his continued service. Following the RSU grant, his directly held common stock position is 3,615 shares.
Waters Corporation SVP Jianqing Bennett reported equity awards that increase his direct ownership. He received stock options for 4,826 shares at an exercise price of $0.0000 per share and a grant of 986 shares of common stock, both described as grant or award acquisitions.
The common stock grant represents restricted stock units that convert into one share of common stock each upon vesting and settlement. Both the RSUs and the stock options will vest in four equal annual installments, with the first installment scheduled to vest on February 25, 2027, contingent on his continued service with the company.